A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: Implications for clinical resistance in targeted cancer treatment

Cell Cycle

Volumn 4, Issue 3, 2005, Pages 400-406

  Von Bubnoff, Nikolas ^a   Barwisch, Simone ^a,b   Speicher, Michael R ^a,b   Peschel, Christian ^a   Duyster, Justus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

CML; Gleevec; Imatinib; Kinase inhibitors; Ph + ALL; Resistance; Targeted therapy

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER PATIENT; CANCER THERAPY; CELL SCREENING; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG BINDING; DRUG RESISTANCE; GENE AMPLIFICATION; GENE MUTATION; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; MOUSE; NONHUMAN; ONCOGENE; POINT MUTATION; PREDICTION; PROTEIN DOMAIN; PROTEIN EXPRESSION;

EID: 25444460629     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.3.1560     Document Type: Article

References (39)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AR, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
3. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 2001; 293:876-80.
4. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of Bcr/Abl in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99:3472-5.
5. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359:487-91.
6. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique Bcr-Abl gene mutation. Blood 2002; 99:1860-2.
7. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can preexist to the onset of treatment. Blood 2002; 100:1014-8.
8. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-25.
9. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40:69-79.
10. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-14.
11. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19:286-7.
12. Fletcher JA CC, Dimitrijevitch S, von Mehren M, Eisenberg B, Joensuu H, Fletcher CDM, Blanke C, Demetri GD, Heinrich MC. Mechanisms of resistance to imatinib-mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). ASCO Annual Meeting: Proc Am Soc Clin Oncol 2003:Abstract 3275.
13. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127:294-9.
14. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64:5913-9.
15. Heidel F, Breitenbuecher F, Kindler T, Solem FK, Carius B, Thiede C, Cohen PS, Roesel J, Estey EH, Feldman E, Ehninger G, Schiller GJ, Klimek V, Nimer S, DeAngelo D, Giles F, Stone RM, Huber C, Fischer T. Mechanisms of resistance to the FLT3-tyrosine kinase inhibitor PKC412 in patients with AML. Blood 2004; 104:133a.
16. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938-42
17. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62:4236-43.
18. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62:7149-53.
19. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A Novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-Abl-driven K562 cells and is effective against STI571-resistant bcr-abl mutants. Clin Cancer Res 2003; 9:1267-73.
20. von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003; 63:6395-404.
21. O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004; 104:2532-9.
22. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 2004; 305:399-401.
23. +) acute lymphocytic leukemia (ALL). Blood 2004; 104:10a-11a.
24. Mestan J, Weisberg E, Cowan-Jacob SW, Fabbro D, Furet P, Fendrich G, Goutte G, Kempf D, Gaugler M, Griffin JD, Manley PW. AMN107: In vitro profile of a new inhibitor of the tyrosine kinase activity of Bcr-Abl. Blood 2004; 104:546a.
25. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 1990; 247:1079-82.
26. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
27. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and Bcr-Abl phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 Bcr-Abl protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998; 4:1601-72.
28. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105:1652-9.
29. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993; 11:11-5.
30. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzl F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM. Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88:260-7.
31. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16:2190-6.
32. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of Bcr-Abl. Cell 2003; 112:831-43.
33. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, Marynen P, Gilliland DG. Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64:6385-9.
34. Rice GC, Goeddel DV, Cachianes G, Woronicz J, Chen EY, Williams SR, Leung DW. Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells. Proc Natl Acad Sci USA 1992; 89:5467-71.
35. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. PKC 412 FLT3 inhibitor therapy in AML: Results of a phase II trial. Ann Hematol 2004; 83:589-90.
36. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9:5465-76.
37. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103:3669-76.
38. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
39. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.